Since none of the tumors in our cohort had MSI and only one had an MMR mutation, our findings indicate that MMR immunohistochemical loss may be uncorrelated with MMR deficiency in gliomas and therefore it does not represent an optimal marker for selection of cases to be candidate to immune check point inhibitors. Here, MRC1 is linked to glioma.